- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04552873
Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage (NAT-URE)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Perrine BOUCHEIX, MD
- Phone Number: 04 76 76 67 29
- Email: pboucheix@chu-grenoble.fr
Study Contact Backup
- Name: Anaïs ADOLLE
- Phone Number: 04 76 76 67 29
- Email: arcpar@chu-grenoble.fr
Study Locations
-
-
-
Grenoble, France, 38043
- Recruiting
- University Hospital Grenoble
-
Contact:
- Perrine BOUCHEIX, MD
-
Contact:
- Anaïs ADOLLE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged at least 18 years old
- Non-traumatic HSA
- Hyponatremia defined by a natremia less than 135 mmol / L and a high natriuresis, greater than 250 mmol / L despite well-managed saline intakes
Exclusion Criteria:
- Severe cardiac decompensation (LVEF <30%)
- Severe hepatic cirrhosis (PT <30%, ascites), known severe renal failure (GFR <30mL / min / 1.73m²)
- Blood urea> 25 mmol / L in the basal state
- Osmotherapy and diuretics in the last 48 hours
- Ongoing treatment with systemic corticosteroids
- Persons referred to in Articles L1121-5 to L1121-8 of the CSP corresponding to all protected persons: pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure.
- Patient not affiliated to a social security scheme
- Known hypersensitivity to any of the components of ergytonyl
- Contraindications to ergytonyl: taking curative anticoagulants, previously known and treated diabetic patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EXPERIMENTAL GROUP
the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)
|
the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight) If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated. If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered. |
Placebo Comparator: CONTROL GROUP
the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
|
the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To demonstrate the effectiveness of urea therapy in correcting persistent hyponatremia despite adequate management during subarachnoid hemorrhage
Time Frame: 5 DAYS
|
Change in blood serum in mmol / L measured before initiation of treatment and on the day of discontinuation of treatment
|
5 DAYS
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Perrine BOUCHEIX, MD, University Hospital, Grenoble
Publications and helpful links
General Publications
- Hall A, O'Kane R. The Extracranial Consequences of Subarachnoid Hemorrhage. World Neurosurg. 2018 Jan;109:381-392. doi: 10.1016/j.wneu.2017.10.016. Epub 2017 Oct 16.
- Mapa B, Taylor BE, Appelboom G, Bruce EM, Claassen J, Connolly ES Jr. Impact of Hyponatremia on Morbidity, Mortality, and Complications After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. World Neurosurg. 2016 Jan;85:305-14. doi: 10.1016/j.wneu.2015.08.054. Epub 2015 Sep 7.
- Hannon MJ, Behan LA, O'Brien MM, Tormey W, Ball SG, Javadpour M, Sherlock M, Thompson CJ. Hyponatremia following mild/moderate subarachnoid hemorrhage is due to SIAD and glucocorticoid deficiency and not cerebral salt wasting. J Clin Endocrinol Metab. 2014 Jan;99(1):291-8. doi: 10.1210/jc.2013-3032. Epub 2013 Dec 20. Erratum In: J Clin Endocrinol Metab. 2014 Mar;99(3):1096. Javadpur, M [corrected to Javadpour, M].
- Nakajima H, Okada H, Hirose K, Murakami T, Shiotsu Y, Kadono M, Inoue M, Hasegawa G. Cerebral Salt-wasting Syndrome and Inappropriate Antidiuretic Hormone Syndrome after Subarachnoid Hemorrhaging. Intern Med. 2017;56(6):677-680. doi: 10.2169/internalmedicine.56.6843. Epub 2017 Mar 17.
- Hoorn EJ, Zietse R. Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines. J Am Soc Nephrol. 2017 May;28(5):1340-1349. doi: 10.1681/ASN.2016101139. Epub 2017 Feb 7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 38RC19.189
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subarachnoid Hemorrhage
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingSubarachnoid Hemorrhage, Aneurysmal | Subarachnoid Hemorrhage, SpontaneousItaly
-
Medical University InnsbruckRecruitingSubarachnoid Hemorrhage | Subarachnoid Hemorrhage, Aneurysmal | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, CerebralAustria
-
Assiut UniversityNot yet recruitingPost-Traumatic Subarachnoid Hemorrhage
-
IRCCS San RaffaeleFondazione Policlinico Universitario Agostino Gemelli IRCCS; Azienda Ospedaliera... and other collaboratorsRecruitingSubarachnoid Hemorrhage, Aneurysmal | Poor Grade Subarachnoid HemorrhageItaly
-
Methodist Health SystemRecruitingTraumatic Intracranial Subarachnoid HemorrhageUnited States
-
University of CalgaryUnknownIntraventricular Hemorrhage | Aneurysmal Subarachnoid HemorrhageCanada
-
Macmillan Research Group UKCenter for Applied Research & Education; SMS Medical College and HospitalCompletedTraumatic Subarachnoid Haemorrhage
-
University of Texas Southwestern Medical CenterRecruitingSubarachnoid Hemorrhage, AneurysmalUnited States
-
Milton S. Hershey Medical CenterRecruiting
-
Second Affiliated Hospital, School of Medicine,...RecruitingSubarachnoid Hemorrhage, AneurysmalChina
Clinical Trials on Urea
-
University of BrasiliaUniversity of WashingtonCompletedRadiodermatitisBrazil
-
Korea University Guro HospitalHanmi Pharmaceutical Company LimitedCompletedHepatocellular CarcinomaKorea, Republic of
-
Galderma R&DCompleted
-
Galderma R&DCompleted
-
University of BrasiliaCompletedRadiodermatitisBrazil
-
Indonesia UniversityCompletedXerosis CutisIndonesia
-
Helbert Rondon Berrios, MD, MSNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Terminated
-
University of AarhusUnknownComparison of Different Concentrations of Carbamide as Moisturizers in Ichthyosis Vulgaris (Urea-IV)Ichthyosis VulgarisDenmark
-
University Children's Hospital, ZurichRecruitingUrea Cycle DisordersSwitzerland
-
ACO Hud Nordic ABUnknown